Twelve patients, 11 with CEA+ colon cancer and 1 with CEA+ rectal cancer, received a priming vaccination with rV-CEA/TRICOM on day 1, with biweekly booster vaccinations with rF-CEA/TRICOM. This evidence concerns the gene CEACAM5 and malignant colon neoplasm.